This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Steven A. J. Salamon net worth and biography

Steven Salamon Biography and Net Worth

Director of Delcath Systems

Steven Salamon is a co-founder and Portfolio Manager at Rosalind Advisors, Inc., a life sciences focused investment manager established in 2006 (“Rosalind Advisors”). Rosalind Advisors is the investment manager for the Rosalind Funds. Mr. Salamon holds a MBA from the Ivey Business School and an Engineering Physics degree from the University of Toronto. Prior to co-founding Rosalind Advisors, Mr. Salamon worked as an equity analyst at HSBC Securities and RBC Capital Markets (formerly RBC Dominion Securities).

What is Steven A. J. Salamon's net worth?: The estimated net worth of Steven A. J. Salamon is at least $351,616.80 as of May 12th, 2022. Mr. Salamon owns 29,424 shares of Delcath Systems stock worth more than $351,617 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Salamon may own. Learn More about Steven A. J. Salamon's net worth.
How do I contact Steven A. J. Salamon?: The corporate mailing address for Mr. Salamon and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected]. Learn More on Steven A. J. Salamon's contact information.
Has Steven A. J. Salamon been buying or selling shares of Delcath Systems?: Steven A. J. Salamon has not been actively trading shares of Delcath Systems during the past quarter. Most recently, on Thursday, May 12th, Steven A. J. Salamon bought 6,000 shares of Delcath Systems stock. The stock was acquired at an average cost of $4.90 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 29,424 shares of the company's stock, valued at $144,177.60. Learn More on Steven A. J. Salamon's trading history.
Who are Delcath Systems' active insiders?: Delcath Systems' insider roster includes Gerard Michel (CEO), John Purpura (COO), and Steven Salamon (Director). Learn More on Delcath Systems' active insiders.
Are insiders buying or selling shares of Delcath Systems?: During the last twelve months, Delcath Systems insiders bought shares 2 times. They purchased a total of 60,882 shares worth more than $199,961.04. The most recent insider tranaction occured on March, 19th when Director Gil Aharon bought 26,882 shares worth more than $100,001.04. Insiders at Delcath Systems own 17.9% of the company. Learn More about insider trades at Delcath Systems.
Information on this page was last updated on 3/19/2024.

Steven A. J. Salamon Insider Trading History at Delcath Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/12/2022	Buy	6,000	$4.90	$29,400.00	29,424
4/19/2022	Buy	1,600	$6.25	$10,000.00	429,100
6/30/2021	Buy	5,500	$12.76	$70,180.00
6/28/2021	Buy	5,000	$11.56	$57,800.00
6/24/2021	Buy	4,500	$10.90	$49,050.00
11/13/2020	Buy	2,000	$11.51	$23,020.00

Steven A. J. Salamon Buying and Selling Activity at Delcath Systems

Delcath Systems Company Overview

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Today's Range

Now: $11.95

$11.68

$12.62

50 Day Range

MA: $9.87

$8.18

$11.88

2 Week Range

Now: $11.95

$2.60

$12.88

Volume

184,875 shs

Average Volume

283,377 shs

Market Capitalization

$382.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad